Michael L. Nickels, PhD, earned his PhD in Chemistry from the University of Illinois at Urbana-Champaign under Professor John Katzenellenbogen. After completion of an industrial post-doctoral appointment researching both medicinal and the related process chemistry. In 2010, Dr. Nickels joined the Vanderbilt University Medical Center faculty and accepted the role of Technical Director of the… Continue reading Dr. Michael L. Nickels
Team Type: Scientific Advisory Board
We have established a global advisory board (SAB) consist of distinguished academic innovative and dynamic members with long term experience in the field of Oncology and Radioligands research, both at scientific preclinical and clinical fields. Coretag’s SAB will be strengthened further during development of our lead candidates, with tumor indication specifics clinical experts, on an ongoing basis.
Prof. Mark Bartholomä
Prof. Mark Bartholomä, PhD, joined Saarland university faculty since 2018, Heading the Preclinical Radiopharmacy and Research group at department of Radiochemistry Saarland University Medical Center in Homburg, Germany. Mark obtained his PhD in Inorganic Chemistry from the same university, and later followed his research in Nuclear Medicine at Syracuse University, NYC, USA, and Harvard Medical… Continue reading Prof. Mark Bartholomä
Dr. Jeremie Calais
Dr. Jeremie Calais, MD, PhD, is a nuclear medicine physician specialized in cancer imaging and theranostics working at the University of California Los Angeles (UCLA) since 2016. He serves as the Director of the Theranostics and Clinical Research Programs of the Ahmanson Translational Theranostics Division and as an Associate Professor in the Department of Molecular… Continue reading Dr. Jeremie Calais
Prof. Kishore Pillarsetty
Prof. Kishore Pillarsetty is trained in organometallics and radiochemistry and currently heads the Targeted Theranostics Laboratory at Memorial Hospital Research Laboratories of Memorial Sloan Kettering Cancer Center (MSK) in New York, NY. He obtained his PhD from University of Missouri-Columbia, in 2003 followed by post-doctoral fellowship at MSK. He also holds joint appointment as Professor… Continue reading Prof. Kishore Pillarsetty
Dr. Anthony W. Tolcher
Dr. Tolcher is CEO and Founder of NEXT OncologyTM, San Antonio, Texas, a Phase I group that seeks to transform early clinical trials. NEXT has grown to 6 sites worldwide, with Phase 1 units in San Antonio, Austin, Dallas, Texas, Fairfax, Virginia, and two sites in Spain, including Madrid and Barcelona. Previously, Dr. Tolcher served… Continue reading Dr. Anthony W. Tolcher